Personalized voriconazole dosing for blood cancer patients
Part of Blood & lymphatic, Cancer, Infections clinical trials.
This study is testing a personalized way to decide the first maintenance dose of voriconazole, an antifungal medicine for people with blood cancers. It uses a genetic test to help determine the best dose for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 or older) with a blood cancer.
- You are being treated at the Grenoble Alps University Hospital in France.
- You are ready to start voriconazole, an antifungal medicine, either to treat or prevent infection.
- You agree to have a genetic test (CYP2C19) to see how your body processes the medicine.
- You are not taking certain medicines that interfere with voriconazole (like valproic acid, phenytoin, carbamazepine, or rifampicin).
- You are not pregnant, breastfeeding, or taking part in another study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if using genetic information can help doctors choose the right dose of the antifungal drug voriconazole. It aims to improve treatment and reduce side effects for people with fungal infections.
This study monitors how the antifungal drug isavuconazole works in children's bodies. It aims to find the right dose for treating serious fungal infections.
This trial tests whether using a targeted antifungal medicine (aimed at PTX3) can better prevent serious fungal infections in adults with AML or a related bone marrow disease who will have very low neutrophils. It may help lower the risk of dangerous infections during intensive chemotherapy hospital stays.
This trial tests whether the antifungal drug posaconazole can prevent serious fungal infections in people who are at high risk after a stem cell transplant. If you qualify, you would take posaconazole during your recovery.
This study looks at how much posaconazole stays in your body while you receive it to prevent fungal infections during chemotherapy or after a stem cell transplant. Your care team will use standard posaconazole treatment and may take extra blood samples to understand its levels.
This study tests how well and how safely the antifungal drug isavuconazole works in critically ill adults in intensive care who have a fungal infection (invasive fungal infection). If you are in the ICU with a suspected or confirmed fungal infection, you may be able to join.
Hear when a new Aspergillosis Invasive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.